Literature DB >> 30567891

Splenectomy for breast carcinoma diffusely metastatic to the spleen presenting as severe transfusion-dependent anaemia and thrombocytopaenia.

Rabea Hasadia1, Olga Kazarin2, Orit Sofer3, Katerina Shulman2, Anton Troitsa1, Ricardo Alfici1, Itamar Ashkenazi4.   

Abstract

We report a 48-year-old woman with metastatic infiltrating lobular carcinoma of the breast. Though her metastatic disease remained stable, she was repeatedly admitted for symptomatic anaemia and treated by red blood cell and platelet transfusions with increasing frequency as time elapsed. Abdominal examination and ultrasound revealed splenomegaly (27 cm span). A bone marrow biopsy showed fibrosis and foci of metastatic carcinoma. Splenectomy ameliorated her transfusion-dependent anaemia and thrombocytopaenia. Histopathology revealed multiple foci of metastatic carcinoma and scattered foci of extramedullary haematopoiesis. Differential diagnosis of anaemia and thrombocytopaenia in patients with cancer include bone morrow involvement by cancer cells, iron-deficiency anaemia, microangiopathies and chemotherapy suppression of haematopoiesis. Splenic involvement with cancer is common in patients with multivisceral disease. Many may regard transfusion-dependent severe anaemia and thrombocytopaenia as an end-stage disease in these patients. Nevertheless, palliative splenectomy should be considered in patients with possible hypersplenism who will otherwise survive for a relatively prolonged period of time. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  breast cancer; palliative care; surgical oncology

Mesh:

Year:  2018        PMID: 30567891      PMCID: PMC6303665          DOI: 10.1136/bcr-2017-223453

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  23 in total

1.  An unusual cause of splenomegaly and pancytopenia (secondary hypersplenism).

Authors:  R P CARERE; I L CLEMES
Journal:  Can Med Assoc J       Date:  1962-05-05       Impact factor: 8.262

Review 2.  Palliative care and the cancer patient: current state and state of the art.

Authors:  Jamie H Von Roenn
Journal:  J Pediatr Hematol Oncol       Date:  2011-10       Impact factor: 1.289

3.  Thromboembolic Events Following Splenectomy: Risk Factors, Prevention, Management and Outcomes.

Authors:  Amihai Rottenstreich; Geffen Kleinstern; Galia Spectre; Nael Da'as; Esther Ziv; Yosef Kalish
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

Review 4.  Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases.

Authors:  Klaus Lechner; Hanna Lena Obermeier
Journal:  Medicine (Baltimore)       Date:  2012-07       Impact factor: 1.889

5.  Breast carcinoma diffusely metastatic to the spleen. A report of two cases presenting as idiopathic thrombocytopenic purpura.

Authors:  O W Cummings; M T Mazur
Journal:  Am J Clin Pathol       Date:  1992-04       Impact factor: 2.493

Review 6.  Complications of splenectomy.

Authors:  C H Shatney
Journal:  Acta Anaesthesiol Belg       Date:  1987

7.  Thrombocytopenia due to hypersplenism in oncological disease: partial splenic embolization during palliative treatment.

Authors:  H Beji; C De La Fouchardière; F Desseigne; P Thiesse; B Richioud; F Pilleul
Journal:  Diagn Interv Imaging       Date:  2015-02-27       Impact factor: 4.026

8.  Solid splenic masses: evaluation with 18F-FDG PET/CT.

Authors:  Ur Metser; Elka Miller; Ada Kessler; Hedva Lerman; Gennady Lievshitz; Ran Oren; Einat Even-Sapir
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

9.  Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer.

Authors:  Jae C Chang; Tahir Naqvi
Journal:  Oncologist       Date:  2003

Review 10.  Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron.

Authors:  M Aapro; A Österborg; P Gascón; H Ludwig; Y Beguin
Journal:  Ann Oncol       Date:  2012-05-09       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.